Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 3Ovarian Neoplasms 3Neoplasm Metastasis 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Neoplasms 2Multiple Myeloma 2Melanoma 2Glioma 2Fallopian Tube Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Thyroid Neoplasms 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycystic Ovary Syndrome 1Peritoneal Neoplasms 1Pancreatic Ductal Adenocarcinoma 1Pain 1Monoclonal Gammopathy of Undetermined Significance 1Magnetic Resonance Imaging 1Lymphoma, Follicular 1Lung Neoplasms 1Limited Stage Small Cell Lung Cancer 1Kidney Neoplasms 1Hypothyroidism 1Hyperphagia 1Hepatic Encephalopathy 1Hematologic Neoplasms 1Head and Neck Neoplasms 1

Interventions

Paclitaxel 115Carboplatin 114Cisplatin 46Topotecan 43Gemcitabine 31Cyclophosphamide 31Docetaxel 28Bevacizumab 28liposomal doxorubicin 27Filgrastim 20pembrolizumab 19Peripheral Blood Stem Cell Transplantation 18Taxes 15Drug Therapy 15Hyperthermic Intraperitoneal Chemotherapy 13sargramostim 12olaparib 12Immunohistochemistry 11Chemotherapy, Adjuvant 11Surgical Procedures, Operative 10Therapeutics 9Flow Cytometry 9Etoposide 9oregovomab 8niraparib 8mirvetuximab soravtansine 8Psychiatric Rehabilitation 8Nivolumab 8Amifostine 8rucaparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Ovarian Epithelial × Glucose × Clear all
NCT05116189 2026-03-09

KEYNOTE-B96

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
643 enrolled 17 charts 1 FDA
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡